Business Description
Iconovo AB
ISIN : SE0010868943
Total Employee Number:
12Compare
Compare
Traded in other countries / regions
ICO.Sweden IPO Date
2018-04-06Description
Iconovo AB develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The project is a generic version of the asthma and COPD product Symbicort.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.64 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.19 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.6 | |||||
Beneish M-Score | -1.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -74.5 | |||||
3-Year EBITDA Growth Rate | 39.3 | |||||
3-Year EPS without NRI Growth Rate | 38.6 | |||||
3-Year FCF Growth Rate | 47.3 | |||||
3-Year Book Growth Rate | -37.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.04 | |||||
9-Day RSI | 46.81 | |||||
14-Day RSI | 45.84 | |||||
3-1 Month Momentum % | 6.11 | |||||
6-1 Month Momentum % | 1.25 | |||||
12-1 Month Momentum % | -42.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.7 | |||||
Quick Ratio | 3.7 | |||||
Cash Ratio | 3.7 | |||||
Days Sales Outstanding | 118.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -75.8 | |||||
Shareholder Yield % | -79.53 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 745.01 | |||||
Operating Margin % | -3048.44 | |||||
Net Margin % | -3068.7 | |||||
EBITDA Margin % | -2341.05 | |||||
FCF Margin % | -3261.84 | |||||
OCF Margin % | -2228.1 | |||||
ROE % | -30.34 | |||||
ROA % | -27.34 | |||||
ROIC % | -30.51 | |||||
3-Year ROIIC % | 21.18 | |||||
ROC (Joel Greenblatt) % | -362.97 | |||||
ROCE % | -29.5 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 28.25 | |||||
PS Ratio | 60 | |||||
PB Ratio | 0.65 | |||||
Price-to-Tangible-Book | 2.35 | |||||
EV-to-EBIT | -1.52 | |||||
EV-to-EBITDA | -1.96 | |||||
EV-to-Revenue | 45.94 | |||||
EV-to-Forward-Revenue | 2.14 | |||||
EV-to-FCF | -1.43 | |||||
Price-to-GF-Value | 4 | |||||
| Price-to-Net-Current-Asset-Value | 3.09 | |||||
| Price-to-Net-Cash | 3.09 | |||||
Earnings Yield (Greenblatt) % | -65.97 | |||||
FCF Yield % | -41.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Iconovo AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 1.313 | ||
| EPS (TTM) (kr) | -0.93 | ||
| Beta | 1.7391 | ||
| 3-Year Sharpe Ratio | -1.01 | ||
| 3-Year Sortino Ratio | -1.28 | ||
| Volatility % | 44.69 | ||
| 14-Day RSI | 45.84 | ||
| 14-Day ATR (kr) | 0.05903 | ||
| 20-Day SMA (kr) | 1.092 | ||
| 12-1 Month Momentum % | -42.42 | ||
| 52-Week Range (kr) | 0.906 - 2.79 | ||
| Shares Outstanding (Mil) | 96.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Iconovo AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Iconovo AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-23 | In 100 days | ||
| Second quarter earnings results for 2026 | 2026-07-15 | 1.09 (+0.00%) | ||
| General meeting for 2025 | 2026-05-28 13:00 | 1.18 (-3.29%) | ||
| First quarter earnings results for 2026 | 2026-04-24 | 1.15 (-1.71%) | ||
| Annual report for 2025 | 2026-04-23 | 1.20 (+3.02%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 | 1.12 (-1.32%) | ||
| Third quarter earnings results for 2025 | 2025-10-24 | 2.01 (+1.01%) | ||
| Second quarter earnings results for 2025 | 2025-07-15 | 2.11 (+5.50%) | ||
| General meeting for 2024 | 2025-06-09 13:00 | 1.56 (+0.00%) | ||
| Annual report for 2024 | 2025-04-25 | 1.12 (-34.66%) |
Show
Entries
Iconovo AB Frequently Asked Questions
What is Iconovo AB(OSTO:ICO)'s stock price today?
The current price of OSTO:ICO is kr1.08. The 52 week high of OSTO:ICO is kr2.79 and 52 week low is kr0.91.
When is next earnings date of Iconovo AB(OSTO:ICO)?
The next earnings date of Iconovo AB(OSTO:ICO) is 2026-07-15 Est..
Does Iconovo AB(OSTO:ICO) pay dividends? If so, how much?
Iconovo AB(OSTO:ICO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Iconovo AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers